Q-Line Biotech Ltd
Incorporated in 2010, Q-Line Biotech Ltd.
is engaged in the business of developing, manufacturing and marketing a diverse
range of reagents.[1]
- Market Cap ₹ 1,542 Cr.
- Current Price ₹ 661
- High / Low ₹ 735 / 431
- Stock P/E 27.2
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 22.4 %
- ROE 26.0 %
- Face Value ₹ 10.0
Pros
Cons
- Debtor days have increased from 92.7 to 134 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 183 | 203 | 313 | 342 | |
| 149 | 165 | 242 | 244 | |
| Operating Profit | 34 | 38 | 71 | 98 |
| OPM % | 18% | 19% | 23% | 29% |
| 2 | 3 | -14 | 5 | |
| Interest | 4 | 6 | 15 | 19 |
| Depreciation | 2 | 4 | 7 | 11 |
| Profit before tax | 30 | 31 | 35 | 73 |
| Tax % | 28% | 29% | 55% | 23% |
| 32 | 34 | 19 | 56 | |
| EPS in Rs | 203.81 | 218.67 | 121.97 | 34.24 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 23% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 21% |
| TTM: | 46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 24% |
| Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 16 |
| Reserves | 126 | 160 | 188 | 230 |
| 74 | 97 | 166 | 225 | |
| 51 | 81 | 99 | 87 | |
| Total Liabilities | 252 | 339 | 455 | 559 |
| 23 | 60 | 91 | 158 | |
| CWIP | 12 | 19 | 63 | 19 |
| Investments | 16 | 29 | 0 | 0 |
| 201 | 232 | 302 | 381 | |
| Total Assets | 252 | 339 | 455 | 559 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 25 | -24 | 17 | 16 | |
| -26 | -45 | -77 | -29 | |
| 26 | 17 | 53 | 42 | |
| Net Cash Flow | 25 | -52 | -7 | 29 |
| Free Cash Flow | -5 | -72 | -53 | -19 |
| CFO/OP | 111% | -39% | 36% | 43% |
Ratios
Consolidated / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 66 | 47 | 96 | 134 |
| Inventory Days | 180 | 413 | 225 | 258 |
| Days Payable | 164 | 232 | 139 | 142 |
| Cash Conversion Cycle | 82 | 228 | 183 | 251 |
| Working Capital Days | -44 | 51 | 45 | 62 |
| ROCE % | 16% | 24% | 22% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Capacity Utilization - Clinical Chemistry/Rapid/Elisa Kits (Unit 3) % ・Standalone data |
|
|||
| Geographic Revenue Mix - North India % ・Standalone data |
||||
| Instrument Revenue Share % ・Standalone data |
||||
| Number of Customers Served count ・Standalone data |
||||
| Number of Distributors count ・Standalone data |
||||
| Reagent Revenue Share % ・Standalone data |
||||
| Capacity Utilization - Selectra Pro M Analyzers (Unit 2) % ・Standalone data |
||||
| Manufacturing Capacity - Selectra Pro M Analyzers (Unit 2) units per year ・Standalone data |
||||
Extracted by Screener AI
Documents
Announcements
-
Shareholders meeting
- Q-Line Biotech's 16th AGM held on 30 Sep 2026; all 4 resolutions passed.
-
Shareholders meeting
- 16th AGM scrutinizer report: all four resolutions passed on 30 September 2026.
-
Shareholders meeting
- Q-Line Biotech held 16th AGM; FY26 revenue ₹341.74 crore, PAT ₹55.72 crore, Lucknow plant commissioned.
-
Trading Window
- Trading window closed from October 1, 2026 for half-year results ending September 30, 2026.
-
Updates
- Sent AGM annual report links; AGM on 30 Sept 2026, remote voting 27-29 Sept, KYC reminder.
Concalls
-
Jun 2026Transcript PPT
Business Profile:[1]
Q-Line Biotech is an Indian in-vitro
diagnostics (IVD) company engaged
in developing, manufacturing, marketing
and distributing diagnostic reagents, consumables, point-of-care (POC)
devices and diagnostic equipment.
The company primarily serves
diagnostic laboratories, hospitals
and medical colleges through
a B2B distribution-led model.